140
Participants
Start Date
April 8, 2020
Primary Completion Date
January 26, 2022
Study Completion Date
April 20, 2022
Experimental: Arm A: DRL_RI
Proposed rituximab biosimilar, 100mg or 500mg, concentrate for solution for infusion
Arm B: Rituxan®/Mabthera®
Reference product US- rituximab (Rituxan®) or EU-rituximab (MabThera®), 100mg or 500mg, concentrate for solution for infusion
Altoona Center For Clinical Research, 175 Meadowbrook Lane,, Duncansville
Rheumatology Consultant of Delaware dba Delaware Arthritis, Lewes
Integrative Rheumatology, Charlotte
Articularis Healthcare Group, Inc dba Low Country Rheumatology, Summerville
Medical Research Center, Miami
AppleMed Research Group, LLC, Miami
MedBio Trials, Aventura
Vicis Clinical Research INC, Tampa
Clinical Research of West Florida Inc - Clearwater, Clearwater
Springfield Clinic (Clinic location), Springfield
Trinity Clinical Research LLC, 2008 East Hebron Parkway, Suites 120/114/100,, Carrollton
Accurate Clinical Research-League City, Texas City
Abigail Neiman, Houston
Accurate Clinical Management, LLC, Houston
Laila A Hassan, MD, PA, Houston
Accurate Clinical Research-Houston, 11003 Resource Parkway, Suite 102, Houston
Houston Rheumatology & Arthritis Specialists, Katy
Accurate Clinical Management, LLC, Baytown
Clinical Associates in Research Therapeutics of America, LLC, San Antonio
Accurate Clinical Research, Inc., San Antonio
Arizona Arthritis and Rheumatology Research, PLLC, Phoenix
Inland Rheumatology Clinical Trials Incorporated, Upland
California Allergy and Asthma Medical Group - CRN - PPDS 41230 11th Street West, Suite A, Palmdale
Integral Rheumatology and Immunology Specialist, 140 Southwest 84th Avenue, Suite B, Plantation
Bluegrass Community Research Inc,330 Waller Avenue, Suite 100,, Lexington
Arthritis and Osteoporosis Associates, Freehold
Lead Sponsor
Collaborators (1)
PPD Development, LP
INDUSTRY
Dr. Reddy's Laboratories Limited
INDUSTRY